卵巢癌免疫治疗研究的文献计量学分析  

Bibliometrics analysis of immunotherapy studies for ovarian cancer

作　　者：朱园园 管东东[2] ZHU Yuanyuan;GUAN Dongdong(Department of Obstetrics and Gynaecology,Binzhou Medical University Hospital,Shandong Province,Binzhou 256600,China;Department of Gynaecology,Binzhou Medical University Hospital,Shandong Province,Binzhou 256600,China)

机构地区：[1]滨州医学院附属医院妇产科,山东滨州256600 [2]滨州医学院附属医院妇科,山东滨州256600

出　　处：《妇儿健康导刊》2024年第1期181-185,共5页JOURNAL OF WOMEN AND CHILDREN'S HEALTH GUIDE

摘　　要：目的采用文献计量学分析方法分析卵巢癌免疫治疗的研究现状和趋势。方法以Web of Science数据库核心合集为数据源,利用CiteSpace 6.2.R4软件和VOSviewer 1.6.18软件对2006-2022年发表的卵巢癌免疫治疗相关文献的国家、机构、作者、参考文献及关键词进行可视化分析。结果共有1039篇文献纳入分析,年发文量呈逐年增长趋势,且近3年增长迅速;发文量最多的国家是美国,其次是中国;发文量最多的机构是德克萨斯大学;研究作者中,Odunsi Kunle、Coukos George、Kandalaft Lana E、Coleman Robert L 4位作者出现频次最高;参考文献共被引次数最多的是《Safety and Antitumor Activity of Anti-PD-1 Antibody,Nivolumab,in Patients With Platinum-Resistant Ovarian Cancer》;关键词中,除“卵巢癌”和“免疫治疗”外,“肿瘤微环境”和“免疫检查点抑制剂”与其他关键词关联性最高。结论肿瘤微环境、免疫检查点抑制剂为当前卵巢癌免疫治疗的研究热点,研究肿瘤细胞与肿瘤微环境中的免疫细胞相互作用的分子机制、免疫治疗与其他疗法之间的有效联合是该领域的研究趋势。Objective To analyze the research status and trend of immunotherapy for ovarian cancer by bibliometrics analysis.Methods Using the Web of Science core collection database as data source,CiteSpace 6.2.R4 software and VOSviewer 1.6.18 software were used to take visual analysis on the country,institution,authors,reference and keywords of related literature on immunotherapy for ovarian cancer published between 2006 and 2022.Results A total of 1039 papers were included in the analysis and the annual publication volume was showing an increasing trend year by year,especially in the past three years.The country with the highest number of publication was the United States,followed by China.The institution with the highest number of publication was the University of Texas System.Among the research authors,the highest frequency of appearance was Odunsi Kunle,Coukos George,Kandalaft Lana E and Coleman Robert L.The most frequently cited reference was Safety and Antitumor Activity of Anti-PD-1 Antibody,Nivolumab,in Patients With Platinum-Resistant Ovarian Cancer.Among the keywords,except for“ovarian cancer”and“immunotherapy”,“tumor microenvironment”and“immune checkpoint inhibitor”had the highest correlation with other keywords.Conclusion Tumor microenvironment and immune checkpoint inhibitor are the current research hotspots of immunotherapy for ovarian cancer.The study of the molecular mechanism of interaction between tumor cells and immune cells in the tumor microenvironment and the research of the effective combination of immunotherapy and other therapies are the research trends in this field.

关 键 词：卵巢癌 免疫治疗 文献计量学 可视化分析 

分 类 号：R711.75[医药卫生—妇产科学]